Satellos Bioscience Inc. carries no debt; cash flow comfortably covers obligations.

Satellos Bioscience Inc.'s free cash flow has decreased 35.60% from $-17.41M last year to $-23.60M, signaling decreasing performance

Satellos Bioscience Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Satellos Bioscience Inc. has insufficient data to evaluate this check.

Satellos Bioscience Inc. has a net cash position, so leverage is healthy.

Satellos Bioscience Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Satellos Bioscience Inc. has insufficient data to evaluate this check.

Satellos Bioscience Inc.'s short-term assets of $31.88M exceed its short-term liabilities of $4.11M

Satellos Bioscience Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Satellos Bioscience Inc.'s return on equity of -51.42%, is lower than 15.00%, indicating bad performance

Satellos Bioscience Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Satellos Bioscience Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Satellos Bioscience Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Satellos Bioscience Inc. has negative free cash flow, indicating cash burn

Satellos Bioscience Inc.'s yearly earnings has decreased 27.04% since last year from $-19.58M to $-24.87M, signaling decreasing performance

Satellos Bioscience Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -20.67% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Satellos Bioscience Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Satellos Bioscience Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Satellos Bioscience Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Satellos Bioscience Inc. has insufficient data to evaluate this check.

Satellos Bioscience Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Satellos Bioscience Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Satellos Bioscience Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Satellos Bioscience Inc. has insufficient data to evaluate this check.

Satellos Bioscience Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Satellos Bioscience Inc. has a price-to-book ratio of 8.78x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Satellos Bioscience Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue